The modern marketing maze

Marketing in our industry is not for the faint-hearted, although it is an area where dynamic teams can discover communicative muscles they never knew they had. As digital possibilities emerge at pace, the modern marketing maze offers exciting opportunities, but identifying them amid regulation and digital domination presents a formidable set of challenges. Challenges which, curiously, many relish...
Pharmaceutical pricing - it’s political

Dr Joe Zammit-Lucia on why it is becoming increasingly import for pharma companies to develop new approaches to pricing that have political resonance
The Plan in action

Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the seismic changes that have been occurring in the NHS since the Long Term Plan was published

News

View all

NHS rolls out staff retention scheme

A new ‘transfer window’ lets staff move within the NHS between areas while developing new skills.

16th July 2019

Abcam acquires EdiGene’s cell lines and lysates portfolio

Financial terms of the transaction have not been disclosed and are expected to have a minimal impact on revenue and earnings in the current financial year.

16th July 2019

Bayer wins FDA approval for Gadavist

CAD is the most common type of heart disease in the United States, as up to one half of middle aged men and one third of middle aged women in the US are at risk of developing CAD during their lifetime.

16th July 2019

PRAC recommends new measures for methotrexate

Decisions include restricting who can prescribe these medicines, making warnings on the packaging more prominent and providing educational materials.

16th July 2019

AZ’ Farxiga hit with complete response letter

AstraZeneca has said that it will work closely with the FDA to discuss the next steps.

15th July 2019

Web Exclusives

View all

Taking a wider look at early-stage research

The lack of availability of early-stage research, particularly in online repositories, threatens to hinder scientific progress, says Morressier's Sami Benchekroun

Pharma has a case of innovation fatigue - here's how to treat it

The pharma innovation story isn’t resonating with vital stakeholders: prescribers and payers working in healthcare settings. Data from a global study which surveyed decision-makers in the healthcare sector reveals that only 39% of respondents in the UK saw the pharmaceutical industry as innovative.

Narrowing the provision

The Court of Justice of the European Union (CJEU) has dealt a blow to innovators in two recent significant judgments, addressing questions posed by national courts struggling to judge the eligibility of SPC applications.

How can the pharma industry turn its sustainability ambitions into action?

Amanda Powel-Smith says pharma has a real opportunity to lead the way in how responsible businesses react to societal challenges

Magazine

View more from the latest edition

Patient Files: prostate cancer

Chris James shares his experiences with different treatments for testicular and prostate cancer

SmartPeople: James Merson

James Merson, global therapeutic area head for Infectious Diseases at Janssen Research & Development, believes that through continued advancements in science “we can change the trajectory of health for humanity and strive to make infectious diseases an issue of the past”

Pharmaceutical pricing - it’s political

Dr Joe Zammit-Lucia on why it is becoming increasingly import for pharma companies to develop new approaches to pricing that have political resonance

Company Focus: MedPharm

Jeremy Drummond, senior vice president of Business Development at MedPharm, on the challenges and opportunities of topical delivery

Connected labelling - the final frontier?

However much progress life sciences companies have made in bringing their regulatory information under control, labelling management continues to overshadow these accomplishments. Too often labelling is disconnected from other systems, forcing heavy reliance on manual processes and checks which in turn can cause hold-ups and create an undesirable source of risk, especially across country borders. Agnes Cwienczek delves deeper into the issues and potential remedies

The modern marketing maze

Marketing in our industry is not for the faint-hearted, although it is an area where dynamic teams can discover communicative muscles they never knew they had. As digital possibilities emerge at pace, the modern marketing maze offers exciting opportunities, but identifying them amid regulation and digital domination presents a formidable set of challenges. Challenges which, curiously, many relish...

The promised land?

Brexit was supposed to be an opportunity for the UK to strike trade deals outside the EU, but the going is tough

A true partnership

Michael Goetzl says it’s time for industry to work in true partnership with health systems “at every step of the way” to speed up access to innovation